Reports
Sale
United States HIV Drugs Market Size, Share, Growth, Forecast: By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (Prep); By Drug Class; By Route of Administration; By Distribution Channel; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032
United States HIV Drugs Market Outlook
The United States HIV drugs market is estimated to expand at a CAGR of 4.3% in the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
United States and HIV Drugs Market Growth
United States and many other countries in other regions witness large number of cases of HIV infection. Unites States noted a major spike in the number of new cases according to most recent data, with the southern states taking the highest numbers among all. It was followed by the West, North-East and Midwest parts of the United States. The demand for drugs for the same will be greater to cater to new and existing cases collectively. More testing centers will also help in early detection of HIV positives and, accordingly, people can start with prescribed medicines to protect themselves from very serious harm. Innovation will also help in rising in the market, like creating more multidimensional medicines such that the burden of consuming different pills is minimized, or lesser dosage is required in a particular time.
United States HIV Drugs Market: Market Segmentation
HIV, human immunodeficiency virus, infection is a condition which attacks and weakens the immune system of people. There are three stages of the infection, acute, chronic and the final and most severe acquired immunodeficiency disease (AIDS). HIV medicines can help in viral suppression, by decreasing the viral load which can protect the immune system and prevent transmission too. Some medicines do this by blocking or altering the enzymes that help the virus multiply. Some refrain the virus from decreasing the CD4 cell count, which fight the pathogens or infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on the types of HIV drugs, the market is divided into:
- Antiretroviral Therapy (ART)
- Pre-Exposure Prophylaxis (Prep)
The different classes of HIV drugs are:
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Combination
- Others
The route of administration of the drugs in the include:
- Oral
- Topical
Different distribution channels are divided into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Demand leading the Market Growth
The rising density of HIV-infected people in the population has helped in the production and implementation of HIV drugs. The market is affected by rising government initiatives and campaigns to raise public consciousness about the causes, symptoms, and treatments of HIV. Furthermore, the launch of generic drugs, which are less expensive and chemically similar to branded drugs, is another factor adding to the demand for HIV drugs. Several international organizations provide funds to research institutes for R&D activities in order to develop innovative, accessible, secure, and reliable medicines for successful therapeutic solutions. The aforementioned factors are expected to drive up demand for HIV drugs over the forecast period.
Key Industry Players in the HIV Drugs Market of United States include
The report presents a detailed analysis of the following key players in the HIV drugs market of United States, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Gilead Sciences, Inc
- Janssen Global Services, LLC (Johnson & Johnson
- ViiV Healthcare group of companies (GSK)
- Merck Sharp & Dohme Corp (Merck & Co)
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 United States
7 Opportunities and Challenges in the Market
8 United States HIV Drugs Market Analysis
8.1 Key Industry Highlights
8.2 United States HIV Drugs Historical Market (2018-2023)
8.3 United States HIV Drugs Market Forecast (2024-2032)
8.4 United States HIV Drugs Market by Drug Type
8.4.1 Antiretroviral Therapy (ART)
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Pre-Exposure Prophylaxis (Prep)
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.5 United States HIV Drugs Market by Drug Class
8.5.1 Nucleoside Reverse Transcriptase Inhibitors
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Multi-Class Combination Products
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Protease Inhibitors
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 HIV Integrase Strand Transfer Inhibitors
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Non-Nucleoside Reverse Transcriptase Inhibitors
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
8.5.6.1 Historical Trend (2018-2023)
8.5.6.2 Forecast Trend (2024-2032)
8.5.7 Fusion Inhibitors
8.5.7.1 Historical Trend (2018-2023)
8.5.7.2 Forecast Trend (2024-2032)
8.5.8 Combination
8.5.8.1 Historical Trend (2018-2023)
8.5.8.2 Forecast Trend (2024-2032)
8.5.9 Others
8.6 United States HIV Drugs Market by Route of Administration
8.6.1 Oral
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Topical
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 United States HIV Drugs Market by Distribution Channel
8.7.1 Hospital Pharmacies
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Retail Pharmacies
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Online Pharmacies
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Others
9 Market Dynamics
9.1 SWOT Analysis
9.1.1 Strengths
9.1.2 Weaknesses
9.1.3 Opportunities
9.1.4 Threats
9.2 Porter’s Five Forces Analysis
9.2.1 Supplier’s Power
9.2.2 Buyers Power
9.2.3 Threat of New Entrants
9.2.4 Degree of Rivalry
9.2.5 Threat of Substitutes
9.3 Key Indicators for Demand
9.4 Key Indicators for Price
10 Value Chain Analysis
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Gilead Sciences, Inc
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Janssen Global Services, LLC (Johnson & Johnson)
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 ViiV Healthcare group of companies (GSK)
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Merck Sharp & Dohme Corp (Merck & Co)
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Others
12 Key Trends and Developments in the Market
Key Questions Answered in the Report
The market is estimated to grow at a CAGR of 4.3% between 2024 and 2032.
The major drivers of the industry include rising population, growing disposable incomes, demand for prevention of infection, and the rising availability of affordable and innovative drugs.
The increasing government initiatives and campaigns to raise public consciousness awareness about the disease is an important industry trend.
The HIV drug types include antiretroviral therapy (ART) and pre-exposure prophylaxis (Prep).
The various classes of HIV drugs are nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist, fusion inhibitors, and combination, among others.
Oral and topical forms of drug are available.
Different distribution channels involve hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The leading players in the market are Gilead Sciences, Inc, Janssen Global Services, LLC (Johnson & Johnson, ViiV Healthcare group of companies (GSK), Merck Sharp & Dohme Corp (Merck & Co), among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER